Mindbio Therapeutics CEO Provides Update on Depression Trial & Novel Discoveries in Psychedelics Research
Mindbio Therapeutics CEO Provides Update on Depression Trial & Novel Discoveries in Psychedelics Research
VANCOUVER, BC / ACCESSWIRE / September 14, 2023 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), Chief Executive Officer Justin Hanka provides corporate update on depression trials and other important developments in the Company in this video address to shareholders.
温哥华，BC/ACCESSWIRE/2023年9月14日/MindBio Treateutics Corp.(CSE：mBio)(法兰克福：WF6)，(“公司“或”MindBio“)，首席执行官贾斯汀·汉卡在这段向股东发表的视频讲话中介绍了公司关于抑郁症试验和其他重要发展的最新情况。
In this video, Justin Hanka, Chief Executive Officer of MindBio, discusses:
在这段视频中，MindBio首席执行官贾斯汀·汉卡讨论了：
-Progress in MindBio's Phase 2a Microdosing Clinical Trial using MB22001, a proprietary form of LSD for Microdosing.
-MindBio公司使用MB22001进行的2a期微剂量临床试验的进展，MB22001是一种用于微剂量的专有形式的LSD。
-A breakthrough genetic discovery important to predicting patient vulnerability in certain genotypes
-一项突破性的基因发现，对预测某些基因类型的患者易感性很重要
-The unexpected discovery of sleep improvement from MB22001 use, including increases in total time of sleep and REM sleep from 3200 days of sleep data
-使用MB22001意外发现睡眠改善，包括从3200天的睡眠数据增加总睡眠时间和快速眼动睡眠
The company is expecting a top line read out from its Phase 2a Depression trial by the end of the year.
该公司预计，今年年底将公布2a期抑郁症试验的营收数据。
We invite you to join us in support of creating a brighter future for mental health.
我们邀请您加入我们，支持为心理健康创造更美好的未来。
Receive our latest updates here:
点击此处接收我们的最新更新：
Follow MindBio on LinkedIn:
在LinkedIn上关注MindBio：
Follow CEO Justin Hanka on LinkedIn:
在领英上关注首席执行官贾斯汀·汉卡：
For further information, please contact:
如需更多信息，请联系：
Justin Hanka, Chief Executive Officer
61 433140886
justin@mindbiotherapeutics.com
首席执行官贾斯汀·汉卡
61 433140886
邮箱：justin@Mind BioTreateutics.com
About MindBio Therapeutics
关于MindBio治疗学
MindBio is a biotech/biopharma company focused on creating novel and emerging treatments for mental health conditions and is conducting world first take-home LSD-Microdosing human clinical trials. MindBio is a leader in microdosing of psychedelic medicines and is advancing its drug and technology protocols through clinical trials. MindBio has developed a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed Phase 1 clinical trials microdosing Lysergic Acid Diethylamide (LSD) in 80 patients, has a Phase 2 clinical trial in development microdosing LSD in patients with Major Depressive Disorder and a Phase 2 clinical trial in development microdosing LSD in late stage cancer patients experiencing existential distress. MindBio invests in research that forms the basis for developing novel and clinically proven treatments including digital technologies and interventions to treat debilitating health conditions such as depression, anxiety and other related mental health conditions.
MindBio是一家生物技术/生物制药公司，专注于为精神健康疾病创造新的和新兴的治疗方法，并正在进行世界上第一个带回家的LSD微剂量人体临床试验。MindBio是迷幻药物微剂量领域的领先者，正在通过临床试验推进其药物和技术方案。MindBio已经开发了一个开发治疗方法的多学科平台，并参与了迷幻药物的开发和数字治疗，已经完成了在80名患者中使用微剂量麦角酸二乙酰胺(LSD)的第一阶段临床试验，在开发针对严重抑郁障碍患者的微剂量LSD的第二阶段临床试验，以及在开发微剂量LSD用于经历生存困境的晚期癌症患者的第二阶段临床试验。MindBio投资于研究，这些研究构成了开发新型和临床验证的治疗方法的基础，包括数字技术和干预措施，以治疗抑郁症、焦虑症和其他相关精神健康疾病等令人衰弱的健康状况。
Cautionary Note Concerning Forward-Looking Statements:
有关前瞻性陈述的注意事项：
The press release contains "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "budget," "believe," "project," "estimate," "expect," "scheduled," "forecast," "strategy," "future," "likely," "may," "to be," "could," "would," "should," "will" and similar references to future periods or the negative or comparable terminology, as well as terms usually used in the future and conditional. Forward-looking statements are based on assumptions as of the date they are provided. However, there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.
该新闻稿包含适用证券法所指的“前瞻性陈述”。前瞻性陈述可以用下列词语来识别：“预期”、“打算”、“计划”、“预算”、“相信”、“项目”、“估计”、“预期”、“预定”、“预测”、“战略”、“未来”、“可能”、“可能”、“将是”、“可能”、“将”、“应该”，“将”和类似的对未来期间或否定或可比术语的引用，以及通常用于未来和有条件的术语。前瞻性陈述是基于截至提供这些陈述之日的假设。然而，不能保证这些假设将反映这些项目或因素的实际结果。
Additionally, there are known and unknown risk factors that could cause the Company's actual results and financial conditions to differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important risk factors that could cause actual results and financial conditions to differ materially from those indicated in the forward-looking statements, include among others: general economic, market and business conditions in Canada and Australia; market volatility; unforeseen delays in timelines for any of the transactions or events described in this press release. All forward-looking information is qualified in its entirety by this cautionary statement.
此外，还有一些已知和未知的风险因素可能会导致公司的实际结果和财务状况与前瞻性陈述中指出的大不相同。因此，您不应依赖这些前瞻性陈述中的任何一种。可能导致实际结果和财务状况与前瞻性陈述中指出的大不相同的重要风险因素包括：加拿大和澳大利亚的总体经济、市场和商业状况；市场波动；本新闻稿中描述的任何交易或事件的时间安排的意外延迟。所有前瞻性信息均受本警告性声明的限制。
The Company disclaims any obligation to revise or update any such forward-looking statement or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
公司没有义务修改或更新任何此类前瞻性陈述，也没有义务公开宣布对本文中包含的任何前瞻性信息的任何修改结果，以反映未来的结果、事件或发展，除非法律另有要求。
Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
加拿大证券交易所及其监管服务提供商(该术语在加拿大证券交易所的政策中定义)均不对本新闻稿的充分性或准确性承担责任。
SOURCE: MindBio Therapeutics
资料来源：MindBio治疗